|
|
Takako |
|
Yoshida-Moriguchi |
|
Drug Discovery Scientist and Program Lead |
Sai Life Sciences |
https://proventainternational.com/wp-content/uploads/2022/03/Takako-Moriguchi-1.jpg |
Takako Yoshida-Moriguchi is an established scientist and program leader in the area of rare disease drug discovery science. She was Group Head of Rare Neuromuscular diseases group at Sanofi Genzyme Drug discovery department, and now leads the Biology group at Sai Life Sciences Exploratory Biology Facilities in Boston. She has pursued Drug discovery research to treat rare and metabolic diseases by utilizing various modalities including small molecule, antisense oligonucleotide, gRNA, bispecific antibodies, and AAV in global pharma and startup settings. |
|
|
Gene |
|
Petrella |
|
Senior Director, Discovery Business Development |
Sai Life Sciences Ltd |
https://proventainternational.com/wp-content/uploads/2022/03/Gene-Petrella.jpg |
Gene Petrella is a classically trained biochemist and cell biologist who has dedicated the past 25 years to technology development and drug discovery in both biotech and large pharmaceutical companies. A co-inventor of Thermofluor® (differential scanning fluorimetry), Gene led 3 -Dimensional Pharmaceutical’s Biophysics and HTS team, helping to position 3DP for a successful IPO and big pharma collaboration.
At the Novartis Institutes for Biomedical Research Gene served as drug discovery liaison to collaborating academic institutions, co-founded and built the Target Identification Proteomics platform, and spearheaded an institute-wide effort to directly target disease-causing RNA.
Leveraging his technology and drug discovery expertise, Gene founded TargetRNA Inc., a startup deploying a novel biophysics and computational platform to discover small molecule therapeutics acting directly on RNA.
Most recently, at Wave Life Sciences Gene led platform technologies ranging from RNA editing to in vivo biology.
Gene received his BS in Biology from Rutgers University, his PhD in Biochemistry from Georgetown University School of Medicine, and conducted postdoctoral studies at Johns Hopkins University School of Medicine |
|
|
Marija |
|
Tadin-Strapps |
|
Vice President & Head, Target Sciences |
Pfizer |
https://proventainternational.com/wp-content/uploads/2022/05/Marija-Tadin-Strapps-1.jpg |
Marija Tadin-Strapps is Vice President & Head, Target Sciences (TS). In this role Marija leads efforts to generate novel drug target hypotheses in areas of emerging science utilizing human genetics, functional genomics, AI/Machine Learning, and data mining tools, as well as experimental hypotheses validation to deliver differentiated targets. TS partners with other teams across ES&I, most notably the Centers for Therapeutic Innovation (CTI) as well as disease biology and technology line teams working across disease areas of interest to Pfizer. Marija brings over 15 years of industry experience in organizations ranging from early start up and small biotech to large pharma, spanning RNA therapeutics, cell therapy, and the use of human genetics and functional genomics for new target validation, biomarker discovery and translational research across multiple disease areas. Prior to joining Pfizer, Marija was at SQZ Biotechnologies after her stint as Head of Biology at Omega Therapeutics. Before Omega, Marija worked for ten years at Merck & Co. Marija earned her B.A. degree in Biology with honors from Goucher College and her Master and Doctorate degrees in Genetics and Development from Columbia University. She has authored multiple peer-reviewed publications on the use of chemically modified siRNAs and the use of human genetics for new target discovery. |
|
|
Shilpi |
|
Arora |
|
Senior Vice President, Discovery Research |
Transition Bio |
https://proventainternational.com/wp-content/uploads/2021/09/shilpi-arora.jpeg |
Shilpi is the SVP of Discovery Research at Transition Bio. Shilpi has over 15 years of experience in leading multiple aspects of drug discovery, target ID/ validation, pharmacology, and translational sciences. Prior to Transition Bio, Shilpi was VP of Discovery and Translation Biology at Exo Therapeutics. Before that, Shilpi held leadership positions at X-Chem Pharmaceuticals and Constellation Pharmaceuticals. She is well-published in the fields of cancer genomics and biomarkers, pharmacology, cellular signaling and identification of new targets. Shilpi received an M.S. and Ph.D. in Cancer Biology from AIIMS, India. She completed her post-doctoral studies at Sanford Burnham Institute and UC, Irvine. |
|
|
Sandro |
|
Belvedere |
|
Vice President, Chemistry |
Avicenna Biosciences, Inc. |
https://proventainternational.com/wp-content/uploads/2021/09/Sandro-Belvedere.jpg |
Dr. Belvedere is Vice President of Chemistry at Avicenna Biosciences. Bio. Dr. Belvedere is an experienced research and development leader, having successfully delivered clinical candidates and directed programs across a broad range of therapeutic areas. Dr. Belvedere’s previous drug development experience includes directing discovery, development, and manufacturing programs at Forkhead Biotherapeutics and ARMGO Pharma, and work on central nervous system targets at GlaxoSmithKline. In addition, at Aton Pharma, Dr. Belvedere contributed to the discovery of new histone deacetylase inhibitors, leading to the oncology drug SAHA (Vorinostat). He is a named inventor on twenty-one United States patents. Dr. Belvedere holds a Ph.D. in chemistry from Columbia University, a Master of Science degree in chemistry from the University of Rochester, and a graduate degree (Laurea) from the University of Rome. |
|
|
Svetlana |
|
Belyanskaya |
|
Vice President, Biology |
Anagenex |
https://proventainternational.com/wp-content/uploads/2021/10/Svetlana-Belyanskaya.jpg |
Svetlana is an accomplished scientific leader in the field of small molecule drug discovery and an expert in the DNA encoded library (DEL) platform. She was involved in the development of DEL platform for 20 years and successfully led a team of scientists on multiple scientific programs. She was instrumental in discovering the first DEL-sourced molecule to progress into clinical trials. Svetlana has deep expertise in biochemistry, molecular biology, cell biology and is very passionate about the future development of DEL technology with the goal to find novel quality leads that bring value to the treatment of diseases with unmet medical needs. |
|
|
Ann |
|
Boriack-Sjodin |
|
Vice President, Molecular Discovery |
Accent Therapeutics |
https://proventainternational.com/wp-content/uploads/2021/09/Ann-Boriack-Sjodin.jpg |
Ann Boriack-Sjodin, Ph.D. is Vice President of Molecular Discovery at Accent Therapeutics. She has a passion for early-stage drug discovery, with contributions to dozens of targets spanning multiple disease indications and experience in large organizations (Biogen, AstraZeneca) and small biotech (Epizyme, Accent). Ann joined Accent Therapeutics in 2017 where she is applying her experience in novel target drug discovery to RNA modifying proteins utilizing both internal and external resources. She has contributed to more than 50 publications and over 20 patents in her career. |
|
|
Brent |
|
Cezairliyan |
|
Vice President, Biology |
Octagon Therapeutics |
https://proventainternational.com/wp-content/uploads/2022/03/Brent-Cezairliyan.jpg |
Brent Cezairliyan, Ph.D. received his doctoral training in biochemistry and biophysics at MIT, studying the regulation of transmembrane signaling in the unfolded protein response. His postdoctoral work at Massachusetts General Hospital resulted in the development of quantitative models of signaling and exoproduct production of microbial pathogens based on their metabolism and growth in complex substrates. As Vice President of Biology at Octagon Therapeutics, Dr. Cezairliyan has led the autoimmune disease metabolism research program to develop novel targeted small molecule therapeutics that suppress autoimmune responses in pathogenic lymphocytes. |
|
|
Kuan-Ju |
|
Chen |
|
Associate Principal Scientist |
Insmed, Inc. |
https://proventainternational.com/wp-content/uploads/2022/04/Kuan-Ju-Chen-New.jpg |
Dr. Kuan-Ju Chen is an Associate Principal Scientist at Insmed Incorporated, NJ, where she is part of a team developing novel, targeted therapies to help serve the critical unmet needs of patients battling serious rare diseases. Kuan has built expertise in pharmaceutical sciences and drug delivery through Ph.D. training at UCLA and Post-doc training at MIT in nanoparticle-based delivery systems for therapeutics and diagnostics. At Insmed, she leads preclinical work developing various in vitro assays as well as evaluating novel therapeutics in different in vivo models for autoimmune, infection, inflammation, and oncology. |
|
|
Jijun |
|
Dong |
|
Vice President, Biologics |
Xilio Therapeutics, Inc. |
https://proventainternational.com/wp-content/uploads/2022/03/Jijun-Dong.jpg |
Dr. Dong serves as Vice President, Biologics at Xilio Therapeutics, where her team is developing geographically precise solutions (GPS) platform to engineer novel molecules, including cytokines and other biologics, that are designed to optimize their therapeutic index by geographically localizing their activity inside tumors. Prior to Xilio, Dr. Dong led biologics research at Cygnal Therapeutics and Alkermes Inc, developing a broad range of molecules, including cytokines, mono-specific antibodies or multi-specific antibody-cytokine fusions for immunotherapy. Prior to joining Alkermes Inc, Dr. Dong held positions of increasing responsibilities at Novartis Institutes for Biomedical Research (NIBR), leading biologic programs from early target validation to clinical candidate nomination for the treatment of cardiovascular and metabolic diseases. Dr. Dong received her Ph.D. in Biochemistry from Emory University and completed her postdoctoral training at Whitehead Institute for Biomedical Research, studying protein misfolding and its relevance in normal biology as well as in human diseases. |
|
|
Larry |
|
Jolivette |
|
Vice President, Head of DMPK |
Proteovant Therapeutics |
https://proventainternational.com/wp-content/uploads/2022/04/Larry-Jolivette.jpg |
Larry J. Jolivette is the head of DMPK at Proteovant Therapeutics. He and his colleagues are focused on developing targeted protein degraders for perceived “undruggable” and novel drug targets. Prior to joining Proteovant, he attained over 20 years of both small and large molecule drug discovery experience at GlaxoSmithKline across multiple therapeutic areas, including cardiovascular, renal, oncology, respiratory, CNS and infectious diseases. He has an accomplished record in preclinical pharmacokinetics, NCE metabolism, and translational strategies for human pharmacokinetic and clinical dose prediction. Larry obtained a BS in Chemistry from Southern University and a PhD in Pharmacology from University of Rochester. |
|
|
Matthew |
|
Kennedy |
|
Executive Director, Neuroscience |
Merck & Co. |
https://proventainternational.com/wp-content/uploads/2022/05/Matthew.jpg |
|
|
|
Paul |
|
Lang |
|
US Head In Vitro Biology, Integrated Drug Discovery |
Sanofi |
https://proventainternational.com/wp-content/uploads/2022/05/Paul-Lang.jpg |
|
|
|
Magdalene |
|
Moran |
|
President & Chief Scientific Officer |
Caraway Therapeutics |
https://proventainternational.com/wp-content/uploads/2022/05/Magdalene-Moran.jpg |
Magdalene Moran, PhD., is a leading scientific researcher in the discovery and early development projects in multiple disease areas. She is a noted expert in the Transient Receptor Potential (TRP) family of ion channels.
Prior to joining Caraway Therapeutics, Dr. Moran was the Senior Vice President of biology at Hydra Biosciences, where she was part of the scientific team for over 15 years. She led discovery and early development projects in pain, pulmonary, CNS, and renal diseases, resulting in six development candidates in six years. In addition, Dr. Moran was the scientific representative for business development activities and coordinated the scientific advisory and medical advisory boards. Before Hydra, Dr. Moran served as a researcher in the laboratory of ion channel expert Dr. David Clapham at Children’s Hospital in Boston, where she studied the basal transcription machinery and cloned several novel ion channels.
Dr. Moran received her bachelor’s degree in biology with a concentration in neuroscience from Williams College and earned her doctorate degree in neurobiology from Harvard University. |
|
|
Joe |
|
Patel |
|
Vice President, Structural Biology |
Treeline Biosciences |
https://proventainternational.com/wp-content/uploads/2021/09/Joe-Patel-edited.jpg |
Joe is currently accountable for the Molecular Sciences group at Treeline Biosciences, a new oncology biotech focused on drugging challenging targets.
After completing graduate studies in protein crystallography at Cambridge University, he took on roles of increasing responsibility at Astex Pharmaceuticals, AstraZeneca UK & US, and C4 Therapeutics with a focus on small molecule drug discovery using fragment-based drug discovery and targeted protein degradation. |
|
|
Matthew |
|
Wagoner |
|
Global Head, Investigative Toxicology |
Takeda Pharmaceuticals |
https://proventainternational.com/wp-content/uploads/2022/01/Matthew-Wagoner.jpg |
Matt Wagoner leads the Global Investigatory Toxicology team at Takeda Pharmaceuticals, where their team applies complex in vitro models and in silico approaches as predictive and mechanistic tools to help make safer medicines. Before Takeda, Matt led the mRNA safety strategy for AstraZeneca Pharmaceuticals, and worked to develop and deploy in vitro and in vivo models in support of oncology and cardiovascular drug discovery projects.
In the academic arena, Matt co-taught a drug discovery course at Simmons College in Boston. He received his PhD in Molecular and Cellular Pharmacology from the University of Wisconsin-Madison and bachelors in biochemistry from the University of Illinois Urbana Champaign. In lieu of hobbies, Matt has four kids and a debilitating addiction to home improvement projects. |
|
|
Jeremy |
|
Wilbur |
|
Senior Director Early Research, Head of Protein Science |
Relay Therapeutics |
https://proventainternational.com/wp-content/uploads/2021/09/Jeremy-Wilbur.png |
Jeremy is the Head of Structural Biology at Relay Therapeutics, a company founded on the notion that understanding protein conformational dynamics will usher in a new era of targeted drug discovery. At Relay, in addition to leading structural biology, Jeremy is part of the Early Research Leadership Team and works on the new target portfolio. Previously, Jeremy held positions in antibody lead discovery and protein biophysics and helped move multiple programs to clinical trials. Jeremy completed postdoctoral work at UC Berkeley and graduate work in Biophysics at UCSF. Jeremy’s career has been spent trying to translate fundamental insights in protein biophysics to the cellular level and ultimately to understanding and modifying the course of the disease. |
Le Meridien Cambridge
Payment Securely powered by stripe
